- Home
- PGZ vs IMA Comparison
PGZ vs IMA Comparison
Compare PGZ & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PGZ | IMA |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.6M | 66.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PGZ | IMA |
|---|---|---|
| Price | $8.74 | $4.08 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 20.5K | 10.7K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 12.26% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $800,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.70 | $3.90 |
| 52 Week High | $10.58 | $9.10 |
Technical Indicators
Market Signals| Indicator | PGZ | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 32.46 | 30.51 |
| Support Level | N/A | $3.92 |
| Resistance Level | $10.50 | $6.13 |
| Average True Range (ATR) | 0.11 | 0.19 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 3.85 | 21.95 |
Price Performance
Historical ComparisonAbout PGZ Principal Real Estate Income Fund of Beneficial Interest
Principal Real Estate Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to provide high current income with capital appreciation by investing in commercial real estate-related securities. The company does its investments in USA, Australia, Japan, France, Great Britain, Canada, Hong Kong, Singapore, South Korea, British Virgin Islands and more.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company developing therapeutics for patients with immunological, autoimmune and inflammatory diseases. The company's flagship asset, IMG-007, is a non-depleting anti-OX40 monoclonal antibody that binds specifically to OX40 receptor on activated T cells to block receptor binding to OX40 ligand (OX40L). IMG-007 is being developed to potentially treat multiple autoimmune and inflammatory diseases and disorders. The company operates in a single segment.